- Home
- TLPH vs IMRN Comparison
TLPH vs IMRN Comparison
Compare TLPH & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- IMRN
- Stock Information
- Founded
- TLPH 2005
- IMRN 1994
- Country
- TLPH United States
- IMRN Australia
- Employees
- TLPH N/A
- IMRN N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- IMRN Health Care
- Exchange
- TLPH Nasdaq
- IMRN Nasdaq
- Market Cap
- TLPH 11.1M
- IMRN 9.2M
- IPO Year
- TLPH 2011
- IMRN N/A
- Fundamental
- Price
- TLPH $0.91
- IMRN $1.89
- Analyst Decision
- TLPH Strong Buy
- IMRN Strong Buy
- Analyst Count
- TLPH 1
- IMRN 1
- Target Price
- TLPH $6.00
- IMRN $5.00
- AVG Volume (30 Days)
- TLPH 7.3M
- IMRN 47.9K
- Earning Date
- TLPH 11-12-2025
- IMRN 08-29-2025
- Dividend Yield
- TLPH N/A
- IMRN N/A
- EPS Growth
- TLPH N/A
- IMRN N/A
- EPS
- TLPH N/A
- IMRN N/A
- Revenue
- TLPH $27,000.00
- IMRN $4,777,422.00
- Revenue This Year
- TLPH N/A
- IMRN N/A
- Revenue Next Year
- TLPH $14,533.26
- IMRN N/A
- P/E Ratio
- TLPH N/A
- IMRN N/A
- Revenue Growth
- TLPH N/A
- IMRN 48.63
- 52 Week Low
- TLPH $0.38
- IMRN $1.50
- 52 Week High
- TLPH $1.20
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- TLPH 77.82
- IMRN 55.95
- Support Level
- TLPH $0.40
- IMRN $1.80
- Resistance Level
- TLPH $1.20
- IMRN $1.94
- Average True Range (ATR)
- TLPH 0.13
- IMRN 0.07
- MACD
- TLPH 0.04
- IMRN 0.01
- Stochastic Oscillator
- TLPH 60.00
- IMRN 76.08
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.